- Short-term, intensive chemoresection with mitomycin C yields a tumor response of 57% in patients with recurrent stage Ta bladder cancer.
- The treatment is associated with fewer clinically significant adverse effects vs standard transurethral resection of the bladder tumor (TURBT).
Why this matters
- Short-term, intensive chemoresection may be a nonsurgical option for older, multimorbid patients.
- The DaBlaCa-13 study of 120 patients with recurrent stage Ta non-muscle invasive bladder cancer (NMIBC) who were randomly assigned to:
- Intervention: intravesical mitomycin C thrice a week for 2 weeks.
- Control: TURBT and adjuvant instillations.
- Primary outcome: tumor response in the intervention group at 4 weeks.
- Funding: Danish Cancer Society; others.
- 57% of patients in the intervention group had completed tumor response (95% CI, 43%-70%).
- No difference in tumor response was observed between low- and high-grade tumors (P=.7).
- A high number of recurrent tumors at baseline was associated with a higher risk for incomplete response (OR, 1.65; P=.02).
- No grade 4 toxicities were reported.
- 3 grade 3 adverse events were observed in the control group.
- Patients in the intervention group reported significantly lower incidence of dysuria (difference, 20%; P=.03), pollakiuria (difference, 25%; P=.007), and palmar skin rash (difference, 18%; P=.002).
- Open label.